Meropenem derivatives and uses thereof

Abstract

The present invention provides novel derivative of β-lactam antibiotics, such as meropenem. The inventive compounds include compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. Also provided are particles (e.g., nanoparticles) and pharmaceutical compositions thereof that are mucus penetrating. The inventive particles and pharmaceutical compositions may be useful in delivering an inventive compound to the respiratory tract of a subject. The invention further provides methods of using and kits including the inventive compounds, particles thereof, and/or pharmaceutical compositions thereof for treating and/or preventing a pulmonary disease (e.g., a respiratory tract infection).

What is claimed is: 
     
         1 . A compound of Formula (I): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof; 
         wherein:
 ---- is a single bond or null; 
    is a single or double bond; 
 R A  is substituted or unsubstituted aliphatic, substituted or unsubstituted carbocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; 
 R B  is —C(═O)—N(Me) 2 , —CH 2 —NH—S(═O) 2 —NH 2 , 
 
       
       
         
           
           
               
               
           
         
         
            ═NH, or 
         
       
       
         
           
           
               
               
           
         
         
           R C  is substituted or unsubstituted aliphatic, substituted or unsubstituted carbocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; 
           R F  is hydrogen or methyl; and 
           provided that when R A  is an unsubstituted C 4  aliphatic, then R C  is an unsubstituted C 6 -C 12  aliphatic, a substituted aliphatic, substituted or unsubstituted carbocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl 
         
       
     
     
         2 . The compound of  claim 1 , wherein R A  is substituted or unsubstituted, 6- to 14-membered aryl. 
     
     
         3 . The compound of  claim 1 , wherein R A  is substituted phenyl. 
     
     
         4 . The compound of  claim 1 , wherein R A  is unsubstituted phenyl. 
     
     
         5 . The compound of  claim 1 , wherein R A  is substituted or unsubstituted alkyl. 
     
     
         6 . The compound of  claim 1 , wherein R A  is substituted C 1-6  alkyl. 
     
     
         7 . The compound of  claim 1 , wherein R A  is unsubstituted C 1-6  alkyl. 
     
     
         8 . The compound of  claim 1 , wherein R A  is substituted 3- to 7-membered, monocyclic carbocyclyl. 
     
     
         9 . The compound of  claim 1 , wherein R A  is unsubstituted 3- to 7-membered, monocyclic carbocyclyl. 
     
     
         10 . The compound of  claim 1 , wherein R C  is substituted or unsubstituted, 6- to 14-membered aryl. 
     
     
         11 . The compound of  claim 1 , wherein R C  is substituted phenyl. 
     
     
         12 . The compound of  claim 1 , wherein R C  is unsubstituted phenyl. 
     
     
         13 . The compound of  claim 1 , wherein R C  is substituted or unsubstituted alkyl. 
     
     
         14 . The compound of  claim 1 , wherein R C  is substituted C 1-6  alkyl. 
     
     
         15 . The compound of  claim 1 , wherein R C  is unsubstituted C 1-6  alkyl. 
     
     
         16 . The compound of  claim 1 , wherein R C  is substituted 3- to 7-membered, monocyclic carbocyclyl. 
     
     
         17 . The compound of  claim 1 , wherein R C  is unsubstituted 3- to 7-membered, monocyclic carbocyclyl. 
     
     
         18 . The compound of  claim 1 , wherein the compound is of Formula (I-A): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof. 
       
     
     
         19 . A compound of Formula (I-A-1): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof. 
       
     
     
         20 . The compound of  claim 1 , wherein the compound is of Formula (I-B): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof. 
       
     
     
         21 . The compound of  claim 1 , wherein the compound is of Formula (I-C): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof. 
       
     
     
         22 . The compound of  claim 1 , wherein the compound is of Formula (I-D): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof. 
       
     
     
         23 . A pharmaceutical composition comprising a compound of any one of  claims 1 - 22 , or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, and optionally a pharmaceutically acceptable excipient. 
     
     
         24 . A pharmaceutical composition comprising:
 a plurality of particles comprising:
 a core comprising a compound of any one of  claims 1 - 22 , or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, and 
 a coating of a surface altering agent surrounding the core, 
 wherein the surface altering agent is a triblock copolymer of the structure:
 (hydrophilic block)-(hydrophobic block)-(hydrophilic block), 
 
 wherein the surface altering agent is present on the outer surface of the core at a density of at least 0.01 surface altering agent per nm 2 ; and 
   optionally a pharmaceutically acceptable excipient.   
     
     
         25 . A pharmaceutical composition comprising:
 a plurality of particles comprising:
 a core comprising a compound of any one of  claims 1 - 22 , or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, and 
 a coating of a surface altering agent surrounding the core, 
 wherein the surface altering agent is a a synthetic polymer having pendant hydroxyl groups on the backbone of the polymer, the polymer having a molecular weight of at least about 1 kDa and less than or equal to about 1000 kDa, and wherein the polymer is at least about 30% hydrolyzed and less than about 95% hydrolyzed, 
 wherein the surface altering agent is present on the outer surface of the core at a density of at least 0.01 surface altering agent per nm 2 ; and 
   optionally a pharmaceutically acceptable excipient.   
     
     
         26 . The pharmaceutical composition of  claim 24  or  25 , wherein the average size of the core ranges from about 50 nm to about 1 μm. 
     
     
         27 . The pharmaceutical composition of  claim 24  or  2 , wherein the average size of the coated particle ranges from about 50 nm to about 1 μm. 
     
     
         28 . The pharmaceutical composition of  claim 24  or  25 , wherein the average smallest cross-sectional dimension of the plurality of coated particles ranges from about 50 nm to about 1 μm. 
     
     
         29 . The pharmaceutical composition of  claim 24  or  25 , wherein the polydispersity index of the cores and/or coated particles is less than about 0.2, less than about 0.15, less than about 0.1, or less than about 0.05. 
     
     
         30 . The pharmaceutical composition of  claim 24  or  25 , wherein the compound, or the pharmaceutically acceptable salt thereof, constitutes at least about 50 wt %, at least about 60 wt %, at least about 70 wt %, at least about 80 wt %, at least about 90 wt %, at least about 95 wt %, or at least about 99 wt % of the core. 
     
     
         31 . The pharmaceutical composition of  claim 24  or  25 , wherein the aqueous solubility of the compound, or the pharmaceutically acceptable salt thereof, is less than 1 mg/mL, less than 0.1 mg/mL, or less than 0.01 mg/mL at 25° C. 
     
     
         32 . The pharmaceutical composition of  claim 24  or  25 , wherein the surface altering agent is present in the pharmaceutical composition in an amount of between about 0.05 wt % and about 5 wt % of the pharmaceutical composition. 
     
     
         33 . The pharmaceutical composition of  claim 24  or  25 , wherein the surface altering agent is covalently attached to the core. 
     
     
         34 . The pharmaceutical composition of  claim 24  or  25 , wherein the surface altering agent is non-covalently adsorbed to the core. 
     
     
         35 . The pharmaceutical composition of  claim 24  or  25 , wherein the surface altering agent is present on the outer surface of the core at a density of at least about 0.01, at least about 0.03, at least about 0.1, at least about 0.3, at least about 1, at least about 3, at least about 10, or at least about 30 surface altering agents per nm 2 . 
     
     
         36 . The pharmaceutical composition of  claim 25 , wherein the polymer comprises pendant hydroxyl groups on the backbone of the triblock copolymer. 
     
     
         37 . The pharmaceutical composition of  claim 24 , wherein at least one hydrophilic block of the triblock copolymer comprises poly(ethylene glycol). 
     
     
         38 . The pharmaceutical composition of  claim 24 , wherein the hydrophobic block of the triblock copolymer is poly(propylene oxide). 
     
     
         39 . The pharmaceutical composition of  claim 24 , wherein the triblock copolymer is poly(ethylene glycol)-poly(propylene oxide)-poly(ethylene glycol). 
     
     
         40 . The pharmaceutical composition of  claim 25 , wherein the polymer is at least about 40% hydrolyzed, at least about 50% hydrolyzed, at least about 60% hydrolyzed, at least about 70% hydrolyzed, at least about 80% hydrolyzed, or at least about 90% hydrolyzed. 
     
     
         41 . The pharmaceutical composition of  claim 25 , wherein the polymer is less than about 95%, less than about 90%, or less than about 80% hydrolyzed. 
     
     
         42 . The pharmaceutical composition of  claim 24 , wherein the two hydrophilic blocks of the triblock copolymer constitute at least about 20 wt %, at least about 30 wt %, at least about 40 wt %, at least about 50 wt %, or at least about 60 wt % of the triblock polymer, and/or less than about 80 wt % of the triblock copolymer. 
     
     
         43 . The pharmaceutical composition of  claim 24 , wherein the molecular weight of each block of the triblock copolymer is independently at least about 1.8 kDa, at least about 2 kDa, at least about 2.5 kDa, at least about 3 kDa, at least about 4 kDa, or at least about 5 kDa. 
     
     
         44 . The pharmaceutical composition of  claim 24 , wherein the molecular weight of the hydrophobic block of the triblock copolymer is at least about 2 kDa, at least about 3 kDa, at least about 4 kDa, or at least about 6 kDa, and/or less than about 20 kDa, less than about 10 kDa, or less than about 8 kDa. 
     
     
         45 . The pharmaceutical composition of  claim 24 , wherein the molecular weight of the triblock copolymer is at least about 2 kDa, at least about 5 kDa, at least about 10 kDa, at least about 20 kDa, at least about 50 kDa, at least about 80 kDa, at least about 100 kDa, or at least about 120 kDa. 
     
     
         46 . The pharmaceutical composition of  claim 24 , wherein the molecular weight of the triblock copolymer is less than about 200 kDa, less than about 180 kDa, less than about 150 kDa, less than about 130 kDa, less than about 100 kDa, less than about 80 kDa, less than about 50 kDa, or less than about 30 kDa. 
     
     
         47 . The pharmaceutical composition of  claim 24 , wherein:
 the molecular weight of the hydrophobic block is at least about 2 kDa; and   the two hydrophilic blocks constitute at least about 15 wt % of the triblock copolymer.   
     
     
         48 . The pharmaceutical composition of  claim 24 , wherein the triblock copolymer is a poloxamer. 
     
     
         49 . The pharmaceutical composition of  claim 24 , wherein the triblock copolymer is PLURONIC® F127. 
     
     
         50 . The pharmaceutical composition of  claim 24  or  25 , wherein the compound, or the pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, is encapsulated in a polymer, a lipid, a protein, or a combination thereof. 
     
     
         51 . The pharmaceutical composition of  claim 24  or  25  further comprising a pharmaceutical agent selected from the group consisting of antifungal agents, antiprotozoan agents, anti-bacterial agents, anti-viral agents, anti-inflammatory agents, anti-proliferative agents, and pain-relieving agents. 
     
     
         52 . The pharmaceutical composition of  claim 24  or  25 , wherein the pharmaceutical composition is suitable for inhalational administration to a subject. 
     
     
         53 . The pharmaceutical composition of  claim 52 , wherein pharmaceutical composition is for treating a respiratory tract disease. 
     
     
         54 . The pharmaceutical composition of  claim 52 , wherein the subject is a human. 
     
     
         55 . The pharmaceutical composition of  claim 53 , wherein the respiratory tract disease is a respiratory tract infection. 
     
     
         56 . The pharmaceutical composition of  claim 55 , wherein the respiratory tract infection is bronchitis or pneumonia. 
     
     
         57 . The pharmaceutical composition of  claim 55 , wherein the respiratory tract infection is caused by a  Pseudomonas  species. 
     
     
         58 . The pharmaceutical composition of  claim 55 , wherein the respiratory tract infection is caused by  Pseudomonas aeruginosa.    
     
     
         59 . The pharmaceutical composition of  claim 53 , wherein the respiratory tract disease is cystic fibrosis. 
     
     
         60 . The pharmaceutical composition of  claim 53 , wherein the coating on the core is present in a sufficient amount to increase the exposure of the compound, or the pharmaceutically acceptable salt thereof, by at least 10% when administered in the pharmaceutical composition compared to the exposure of the compound, or the pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, when administered as a core without the coating. 
     
     
         61 . The pharmaceutical composition of  claim 53 , wherein the coating on the core is present in a sufficient amount to increase the concentration of the compound by at least 10% in the subject when administered in the pharmaceutical composition, compared to the concentration of the compound in the subject when administered as a core without the coating. 
     
     
         62 . A kit comprising:
 a compound of any one of  claims 1 - 22 , or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, or a pharmaceutical composition of any one of  claims 23 - 61 ; and   instructions for administering the compound, the pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, or the pharmaceutical composition.   
     
     
         63 . A method of treating a respiratory tract disease in a subject in need thereof comprising:
 inhalationally administering to the subject a therapeutically effective amount of a compound of any one of  claims 1 - 22 , or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, or a pharmaceutical composition of any one of  claims 23 - 61 .   
     
     
         64 . The method of  claim 63 , wherein the step of administering comprises administering one or more doses comprising independently at least about 0.003 mg, at least about 0.01 mg, at least about 0.03 mg, at least about 0.1 mg, at least about 0.3 mg, at least about 1 mg, at least about 3 mg, at least about 10 mg, or at least about 30 mg of the compound, or the pharmaceutical acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, per kg of body weight of the subject. 
     
     
         65 . The method of  claim 63  or  64 , wherein the step of administering comprises administering two or more doses, wherein the time period between consecutive doses is at least about 6 hours, at least about 8 hours, at least about 12 hours, at least about 36 hours, or at least about 48 hours. 
     
     
         66 . The method of  claim 63 , further comprising sustaining an efficacious level of the compound, or an active metabolite thereof, in the subject for at least 12 hours after administration. 
     
     
         67 . The method of  claim 63 , wherein the subject is a human. 
     
     
         68 . The method of  claim 63 , wherein the respiratory tract disease is a respiratory tract infection. 
     
     
         69 . The method of  claim 68 , wherein the respiratory tract infection is bronchitis or pneumonia. 
     
     
         70 . The method of  claim 68 , wherein the respiratory tract infection is caused by a  Pseudomonas  species. 
     
     
         71 . The method of  claim 68 , wherein the respiratory tract infection is caused by  Pseudomonas aeruginosa.    
     
     
         72 . The method of  claim 63 , wherein the respiratory tract disease is cystic fibrosis. 
     
     
         73 . The method of  claim 63 , wherein the coating on the core is present in a sufficient amount to increase the exposure of the compound, or the pharmaceutically acceptable salt thereof, by at least 10% when administered in the pharmaceutical composition compared to the exposure of the compound, or the pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, when administered as a core without the coating. 
     
     
         74 . The method of  claim 63 , wherein the coating on the core is present in a sufficient amount to increase the concentration of the compound by at least 10% in the subject when administered in the pharmaceutical composition, compared to the concentration of the compound in the subject when administered as a core without the coating.